Ciclo celular/Ponto de verificação
Os inibidores do ciclo celular/ponto de verificação são compostos que interrompem a progressão normal do ciclo celular, particularmente em pontos de verificação regulatórios chave. Esses inibidores são cruciais para estudar a divisão celular, entender a proliferação de células cancerígenas e desenvolver terapias anticâncer. Ao direcionar fases específicas do ciclo celular, esses inibidores podem induzir a parada do ciclo celular, levando à apoptose ou senescência em células de divisão rápida. Na CymitQuimica, oferecemos uma ampla gama de inibidores de alta qualidade do ciclo celular/ponto de verificação para apoiar sua pesquisa em biologia do câncer, biologia celular e desenvolvimento de medicamentos.
Subcategorias de "Ciclo celular/Ponto de verificação"
- Aurora Quinase(96 produtos)
- CDK(505 produtos)
- Ciclo celular/Parada(4 produtos)
- Chk(42 produtos)
- DYRK(48 produtos)
- Dinamina(23 produtos)
- Ferroptose(215 produtos)
- HSP(170 produtos)
- Integrinas(227 produtos)
- Cinesina(68 produtos)
- LIM Quinase(19 produtos)
- Microtúbulo associado(261 produtos)
- PKC(102 produtos)
- PLK(28 produtos)
- ROCK(68 produtos)
- Rho(2 produtos)
- Wee1(15 produtos)
- c-Myc(68 produtos)
Exibir 10 mais subcategorias
Foram encontrados 3495 produtos de "Ciclo celular/Ponto de verificação"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
11-Oxahomoaminopterin
CAS:<p>11-Oxahomoaminopterin exhibits antifolate activity against two folate-requiring microorganisms and inhibited Lactobacillus casei DHFR.</p>Fórmula:C20H21N7O6Pureza:98%Cor e Forma:SolidPeso molecular:455.42L 734217
CAS:<p>L 734217 is an antagonist of the fibrinogen receptor.</p>Fórmula:C18H31N3O4Pureza:98%Cor e Forma:SolidPeso molecular:353.46GR 122222X
CAS:<p>GR 122222X is an inhibitor of topoisomerase II.</p>Fórmula:C26H35N5O11SPureza:98%Cor e Forma:SolidPeso molecular:625.654,5'-Dimethylangelicin-NHS
<p>NHS-modified coumarin, 4,5'-Dimethylangelicin-NHS, shows photochemical activity & photosensitivity.</p>Fórmula:C21H19NO7SCor e Forma:SolidPeso molecular:429.44DNA polymerase-IN-6
CAS:<p>DNA polymerase-IN-6 (Compound 27) exhibits inhibitory activity against DNA polymerase, with EC50 values of 0.33 µM for HCMV, 1.9 µM for HSV-1, 0.76 µM for HSV-2, and 0.066 µM for EBV.</p>Fórmula:C26H28ClFN8O4Cor e Forma:SolidPeso molecular:571.003Dyrk1A/α-synuclein-IN-1
<p>Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual inhibitor of Dyrk1A (IC50: 177 nM) and α-synuclein aggregation (IC50: 10.5 μM).</p>Fórmula:C20H21N5O3SCor e Forma:SolidPeso molecular:411.48N-Nitrosonornicotine
CAS:<p>N-Nitrosonornicotine, a tobacco-specific nitrosamine, exhibits carcinogenic and mutagenic properties, and is capable of inducing micronuclei in C3A cells. Additionally, N-Nitrosonornicotine can form DNA adducts.</p>Fórmula:C9H11N3OCor e Forma:SolidPeso molecular:177.22,5-Di-tert-butyl-1,4-benzoquinone
CAS:<p>2,5-Di-tert-butyl-1,4-benzoquinone is a potent antibacterial agent found primarily in marine Streptomyces sp. VITVSK1, effective against emerging antibiotic resistance. Additionally, it serves as a powerful inhibitor of RNA polymerase.</p>Fórmula:C14H20O2Cor e Forma:SolidPeso molecular:220.31Chk1-IN-5
CAS:<p>Chk1-IN-5 inhibits Chk1, blocking phosphorylation and suppressing colon cancer growth.</p>Fórmula:C18H18FN7O2Cor e Forma:SolidPeso molecular:383.38CDK1-IN-6
<p>CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.</p>Fórmula:C21H22N4OCor e Forma:SolidPeso molecular:346.43DS96432529
<p>DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.</p>Fórmula:C18H26N4O3SCor e Forma:SoildPeso molecular:378.49DNA gyrase B-IN-1
<p>DNA gyrase B-IN-1, a potent inhibitor of P. aeruginosa DNA gyrase B, has IC50 of 2.2 μM with high affinity and stability.</p>Fórmula:C23H18ClF3N6O4SCor e Forma:SolidPeso molecular:566.94MtTMPK-IN-9
<p>MtTMPK-IN-9 moderately inhibits MtbTMPK (IC50: 48 μM), has submicromolar Mycobacterium activity, and is non-toxic, aiding tuberculosis research.</p>Fórmula:C25H26N6O7Cor e Forma:SolidPeso molecular:522.51RECTAS-2.0
CAS:<p>RECTAS-2.0 is a small molecule designed to correct RNA mis-splicing caused by the GLA c.639+919G>A mutation, intended for research in Fabry disease.</p>Fórmula:C18H17ClN4O4Cor e Forma:SolidPeso molecular:388.8053-IN-PP1
CAS:<p>3-IN-PP1: PKD inhibitor (IC50: 94-108 nM for PKD1/2/3), broad anticancer agent for research.</p>Fórmula:C17H18N6Cor e Forma:SolidPeso molecular:306.36β-catenin-IN-8
CAS:<p>β-catenin-IN-8 (Compound 25) is an inhibitor of β-catenin. It effectively lowers the levels of both β-catenin and c-Myc proteins and suppresses Wnt target genes (Fgf20 and Sall4). Additionally, β-catenin-IN-8 exhibits anticancer activity against colorectal cancer and possesses metabolic stability.</p>Fórmula:C15H12ClN3O2SCor e Forma:SolidPeso molecular:333.79Cdc7-IN-18
CAS:<p>Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).</p>Fórmula:C19H21N5OSCor e Forma:SolidPeso molecular:367.47PT109
CAS:PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.Fórmula:C23H31N3OS2Cor e Forma:SolidPeso molecular:429.64LNA-GTP
CAS:<p>LNA-GTP is a nucleotide analog used in the synthesis of oligonucleotides.</p>Fórmula:C11H16N5O14P3Cor e Forma:SolidPeso molecular:535.192'-O-MOE-UTP
CAS:<p>2'-O-MOE-UTP is a nucleotide analog employed in the synthesis of oligonucleotides.</p>Fórmula:C12H21N2O16P3Cor e Forma:SolidPeso molecular:542.22P162-0948
CAS:<p>P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.</p>Fórmula:C20H15FN4O2Cor e Forma:SolidPeso molecular:362.357CDK4/6-IN-13
CAS:<p>Compounds 10B and 10C: potent cdk4/6 inhibitors with low nM activity, great antiproliferative effects, excellent metabolism, and good pharmacokinetics.</p>Fórmula:C25H29N7OCor e Forma:SolidPeso molecular:443.54CDK/HDAC-IN-1
<p>CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.</p>Fórmula:C20H18N4O4Cor e Forma:SolidPeso molecular:378.38CDK7-IN-31
CAS:<p>CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.</p>Fórmula:C27H32F5N6O2PCor e Forma:SolidPeso molecular:598.55CDK6-IN-1
CAS:<p>CDK6-IN-1 (compound 4i) is an inhibitor of CDK6 that suppresses cell growth and induces cell cycle arrest at the G1 phase.</p>Fórmula:C30H23N5Cor e Forma:SolidPeso molecular:453.54CDK4/6-IN-3
CAS:<p>CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.</p>Fórmula:C25H31FN8Pureza:98%Cor e Forma:SolidPeso molecular:462.57SCH-1473759
CAS:SCH-1473759 is an inhibitor of the aurora (IC50s: 4 and 13 nM for Aurora A and B, respectively).Fórmula:C20H26N8OSPureza:98%Cor e Forma:SolidPeso molecular:426.54MKLP2-IN-1
CAS:<p>MKLP2-IN-1 (compound 12a) is an inhibitor of MKLP2 that demonstrates excellent oral bioactivity. In vitro, MKLP2-IN-1 inhibits the ATPase activity stimulated by recombinant MKLP2 microtubules and, in a mouse Calu-6 lung cancer model, it effectively suppresses tumor growth.</p>Fórmula:C23H19BrFN3O2Cor e Forma:SolidPeso molecular:468.318CDK2-IN-39
CAS:<p>CDK2-IN-39 (compound 4) is a CDK2 inhibitor.</p>Fórmula:C14H15N3O4SCor e Forma:SolidPeso molecular:321.352CDK2-IN-40
CAS:<p>CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.</p>Fórmula:C16H21N7O2Cor e Forma:SolidPeso molecular:343.384Dencatistat
CAS:<p>Dencatistat is a highly selective and oral cytidine triphosphate synthase 1 CTPS1 inhibitor specific.CTPS1-IN-2 for B-cell, T-cell lymphomas and solid tumors.</p>Fórmula:C24H27N7O5SPureza:98.85%Cor e Forma:SolidPeso molecular:525.58DENV-IN-6
CAS:<p>DENV-IN-6, a potent anti-DENV (I-IV) and HIV-1 IIIB inhibitor with EC50 ranging 6.8-17.5 μM for DENV and EC50 0.0181 μM for HIV-1.</p>Fórmula:C23H26ClFN4OSCor e Forma:SolidPeso molecular:461MU147
CAS:<p>MU147 is an MRE11 nuclease inhibitor and chemical probe with anticancer properties, exhibiting lethal effects on Ehrlich ascites tumor cells both in vivo and in vitro. It disrupts the MRE11 nuclease-dependent double-strand break repair mechanism without impairing ATM activation. Additionally, MU147 damages the degradation of nascent strands at stalled replication forks and selectively affects BRCA2-deficient cells.</p>Fórmula:C19H13N3O3SCor e Forma:SolidPeso molecular:363.39Kolavenic acid analog
CAS:<p>KAA, an anticancer compound, inhibits centrosome clustering and targets HSET+ yeast and cancer cells.</p>Fórmula:C25H38O4Cor e Forma:SolidPeso molecular:402.57CDK7/12-IN-1
CAS:<p>CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.</p>Fórmula:C25H34N8OCor e Forma:SolidPeso molecular:462.59TREX1-IN-3
CAS:<p>TREX1-IN-3 (Compound 95) is an inhibitor of TREX1 and TREX2, with an IC50 of less than 0.1 μM for TREX1 and less than 1 μM for TREX2, as well as an EC50 of less than 1 μM for HCT116 cells. It is applicable for research in the field of cancer.</p>Fórmula:C24H19ClN6O4Cor e Forma:SolidPeso molecular:490.898MtTMPK-IN-8
<p>MtTMPK-IN-8 inhibits MtbTMPK, has low cytotoxicity, shows 0.78-9.4 μM activity against Mycobacterium, useful for tuberculosis research.</p>Fórmula:C24H24N6O7Cor e Forma:SolidPeso molecular:508.48HPH-15
CAS:<p>HPH-15 is an anti-cell migration compound that inhibits cell movement by binding to hnRNP U or suppressing TGF-β. Additionally, it prevents epithelial-to-mesenchymal transition (EMT). HPH-15 holds potential for research in areas such as anti-tumor metastasis and anti-fibrosis.</p>Fórmula:C19H31N3S4Cor e Forma:SolidPeso molecular:429.73Zeltociclib
CAS:<p>Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.</p>Fórmula:C18H20F3N4O2PCor e Forma:SolidPeso molecular:412.346DL-Alanosine
CAS:<p>DL-Alanosine is an amino acid analog with antitumor activity.</p>Fórmula:C3H7N3O4Cor e Forma:SolidPeso molecular:149.105IIP0943
CAS:<p>IIP0943 is a selective PLK1 (polo-like kinase 1) inhibitor with an IC50 of 5.1 nM for PLK1. It also exhibits inhibitory activity on the proliferation of HCT116 cells, with an IC50 of 0.22 µM. IIP0943 shows potential for research in the field of oncology.</p>Fórmula:C26H28N6O3SCor e Forma:SolidPeso molecular:504.604SR121566A
CAS:SR121566A is a novel non-peptide antagonist of Glycoprotein IIb/IIIa (GP IIb-IIIa).Fórmula:C20H25N5O4SPureza:98%Cor e Forma:SolidPeso molecular:431.51TREX1-IN-4
CAS:<p>TREX1-IN-4 (Compound 96) is an inhibitor of TREX1 and TREX2, exhibiting an IC50 of less than 0.1 μM for TREX1 and an IC50 of less than 1 μM for TREX2. It has an EC50 ranging from 0.1 to 10 μM in HCT116 cells. TREX1-IN-4 is applicable for research in the field of cancer.</p>Fórmula:C24H19ClN6O4Cor e Forma:SolidPeso molecular:490.898CDK2-IN-8
<p>CDK2-IN-8 is a potent CDK2 inhibitor (IC50= 1.74 μM). CDK2-IN-8 exhibits antiproliferative activity. CDK2-IN-8 can be used for the research of melanoma.</p>Fórmula:C22H25N5O3Cor e Forma:SolidPeso molecular:407.47MU1409
CAS:<p>MU1409 is an MRE11 nuclease inhibitor with an IC50 of 12.1 μM. It also inhibits FEN1 and EXO1, with IC50 values of 24.2 μM and 176.4 μM, respectively. MU1409 impacts cellular DNA repair and prevents the degradation of stalled replication forks in BRCA2-deficient cells, making it a promising candidate for studying BRCA2 mutation-induced cancers.</p>Fórmula:C20H14BrN3O3SCor e Forma:SolidPeso molecular:456.312CDK7-IN-17
CAS:<p>CDK7-IN-17, a pyrimidine-based CDK7 inhibitor, shows promise for various cancers, especially with abnormal transcription.</p>Fórmula:C24H26F3N6OPCor e Forma:SolidPeso molecular:502.47Zorubicin
CAS:<p>Zorubicin, a Daunorubicin derivative, targets topoisomerase II, inhibits DNA polymerase, and researches acute leukemia, sarcomas.</p>Fórmula:C34H35N3O10Cor e Forma:SolidPeso molecular:645.66CDK4/6-IN-24
CAS:<p>CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.</p>Fórmula:C32H41N7O3Cor e Forma:SolidPeso molecular:571.713UMPK ligand 1
CAS:<p>UMPK ligand 1 (ZINC07785412) serves as a ligand for uridine monophosphate kinase (UMPK).</p>Fórmula:C15H22N4O5SCor e Forma:SolidPeso molecular:370.424LY309887
CAS:LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (Ki: 6.5 nM). It also has antitumor activity.Fórmula:C19H23N5O6SCor e Forma:SolidPeso molecular:449.48LN-439A
CAS:<p>LN-439A (compound LN-439A) is a novel BAP1 inhibitor that suppresses the growth of basal-like breast cancer by degrading KLF5.</p>Fórmula:C24H26FN3O4Cor e Forma:SolidPeso molecular:439.48KWR095
CAS:<p>KWR095 is an orally active inhibitor of WRN, demonstrating an IC50 of 0.032 μM against WRN ATPase. It disrupts the double-stranded helicase activity of WRN and inhibits tumor cell proliferation, exhibiting antitumor properties.</p>Fórmula:C33H31ClF3N9O4Cor e Forma:SolidPeso molecular:710.105AR-13324 M1 metabolite
CAS:<p>AR-13324 M1 metabolite is a hydrolysis metabolite of AR-13324 mesylate.</p>Fórmula:C19H19N3O2Pureza:98%Cor e Forma:SolidPeso molecular:321.37p38α inhibitor 9
CAS:<p>p38α inhibitor9 (Compound 2015) is a p38α inhibitor that effectively blocks the enzyme activity of p38α, with an IC50 of less than 20 nM. It inhibits MK2T334 phosphorylation and activates Cdc25b and Cdc25c while inactivating Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy, and DNA damage. Additionally, p38α inhibitor9 can suppress colorectal cancer (CRC) metastasis.</p>Fórmula:C27H24FN3O3Cor e Forma:SolidPeso molecular:457.496And1 degrader 1
CAS:<p>And1 degrader 1 (Compound A15) is a degrader of acidic nucleoplasmic DNA-binding protein 1 (And1) that notably induces degradation of And1 in NSCLC cells. When combined with Olaparib (1 μM), And1 degrader 1 at a concentration of 5 μM effectively inhibits proliferation in A549 and H460 cells. This compound is applicable in cancer research studies.</p>Fórmula:C26H27Cl2N3OCor e Forma:SolidPeso molecular:468.42DNA Gyrase-IN-16
CAS:<p>DNA Gyrase-IN-16 (Compound 9) is an inhibitor of DNA gyrase, with an IC50 of 1.609 μM. It exhibits antibacterial properties, effectively inhibiting S. aureus and MRSA, with a MIC of 3.125 μM for both.</p>Fórmula:C17H15N3O3Cor e Forma:SolidPeso molecular:309.319BRD4 Inhibitor-40
CAS:<p>BRD4 Inhibitor-40 (Compound 23) functions as an inhibitor of BRD, effectively targeting BRD4-BD1, BRD4-BD2, BRD2-BD1, and BRD2-BD2, with IC50 values of 16.1, 142.18, 29.35, and 302.35 nM, respectively. It modulates the expression of c-Myc and p21, induces cell cycle arrest in the G1 phase, and inhibits Pkd1-deficient (PN) renal cystic epithelial cells. Additionally, it prevents renal cyst formation in both Madin-Darby canine kidney and embryonic kidney cyst models, and demonstrates renal cyst inhibition activity in mouse models.</p>Fórmula:C27H32N8OCor e Forma:SolidPeso molecular:484.596CDK2/4-IN-2
CAS:<p>CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.</p>Fórmula:C18H20F3N7O3S2Cor e Forma:SolidPeso molecular:503.52BET/Aurora kinase-IN-1
CAS:<p>BET/Aurora kinase-IN-1 (Compound 38) is a dual inhibitor of BET and Aurora kinases. It exhibits antiproliferative activity against various tumor cell lines and demonstrates significant antitumor efficacy in xenograft models of renal cell carcinoma and colon cancer, with tumor growth inhibition (TGI) rates of 45.99% and 53.06%, respectively.</p>Fórmula:C25H30FN7OCor e Forma:SolidPeso molecular:463.55HNC-1664
CAS:<p>HNC-1664 is an orally active inhibitor of RNA-dependent RNA polymerase (RdRP). It exhibits broad-spectrum antiviral activity against coronaviruses, including SARS-CoV-2 wild type and its variants (XBB.1.18, HK.3.1, BF.7.14, BA.1, HCoV-229E, HCoV-OC43), as well as arenaviruses. HNC-1664 also demonstrates anti-infective efficacy in a mouse model infected with the SARS-CoV-2 Delta variant.</p>Fórmula:C12H13FIN3O3Cor e Forma:SolidPeso molecular:393.153IRE1α kinase-IN-5
<p>IRE1α kinase-IN-5 (compound 7) is a potent inhibitor of IRE1α (Ki: 98 nM) and is an ATP-competitive ligand for IRE1α.</p>Fórmula:C28H30N6O3SCor e Forma:SolidPeso molecular:530.64L-I-OddU
CAS:<p>L-I-OddU: Selective anti-EBV, halts virus DNA/protein synthesis. EC50: 0.03 µM, low toxicity (CC50: 1000 nM).</p>Fórmula:C8H9IN2O5Cor e Forma:SolidPeso molecular:340.072′-O-MOE-CMP
CAS:<p>2′-O-MOE-CMP is a nucleotide analogue utilized in the synthesis of oligonucleotides.</p>Fórmula:C12H20N3O9PCor e Forma:SolidPeso molecular:381.28(R)-Atuveciclib
CAS:<p>Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor that inhibits CDK9 / CycT1 with an IC 50 of 13 nM [1].</p>Fórmula:C18H18FN5O2SPureza:98%Cor e Forma:SolidPeso molecular:387.437-Methylguanosine 5′-monophosphate
CAS:<p>7-Methylguanosine 5′-monophosphate (7-Methylguanylic acid) is a component of nucleic acids.</p>Fórmula:C11H16N5O8PCor e Forma:SolidPeso molecular:377.25GR 83895
CAS:<p>GR 83895 is an antagonist of prototype fibrinogen receptor.</p>Fórmula:C29H39N9O8SPureza:98%Cor e Forma:SolidPeso molecular:673.74Rhodblock 1a
CAS:<p>Rhodblock 1a is an inhibitor of the Rho kinase signaling pathway, which disrupts the localization and function of proteins within the Rho pathway. This interference hinders the proper formation of the cleavage furrow during cell division, leading to some cells either failing to form the cleavage furrow or forming a ruptured furrow, resulting in binucleated cells. Rhodblock 1a can be utilized for investigating cell division mechanisms and holds potential for research into cardiovascular diseases and cancer.</p>Fórmula:C20H16N2O2Cor e Forma:SolidPeso molecular:316.353(R)-CSN5i-3
CAS:<p>(R)-CSN5i-3 is CSN5i-3 of the R configuration.</p>Fórmula:C28H29F2N5O2Pureza:99.76% - 99.97%Cor e Forma:SolidPeso molecular:505.56Elacytarabine
CAS:<p>Elacytarabine (M7594 0037), a lipid-conjugated derivative of the nucleoside analog cytarabine, is an antineoplastic drug. It has cytotoxicity in solid tumors.</p>Fórmula:C27H45N3O6Pureza:97.69%Cor e Forma:SolidPeso molecular:507.66CTPS1-IN-1
CAS:<p>CTPS1-IN-1 is a cytidine-5′ triphosphate synthase 1 (CTPS1) inhibitor with potential antitumor activity and can be used to study autoimmune diseases.</p>Fórmula:C21H22N6O4S2Pureza:99.46%Cor e Forma:SolidPeso molecular:486.57GFB-12811
CAS:<p>GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.</p>Fórmula:C22H23F4N5OPureza:98.88%Cor e Forma:SolidPeso molecular:449.44HRO761
CAS:<p>HRO761 is a potent Werne r syndrome RecQ DNA deconjugase (WRN) inhibitor that can be used to study cancers such as colon and stomach cancer.</p>Fórmula:C31H31ClF3N9O5Pureza:98.74% - 99.62%Cor e Forma:SolidPeso molecular:702.08LY3143921 hydrate
CAS:<p>LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].</p>Fórmula:C16H14FN5O2Pureza:98.43%Cor e Forma:SolidPeso molecular:327.31SR 11302
CAS:<p>SR 11302 is an inhibitor of activator protein-1 (AP-1).</p>Fórmula:C26H32O2Pureza:98.65%Cor e Forma:SolidPeso molecular:376.53INCB086550
CAS:<p>INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM.</p>Fórmula:C41H39N7O4Pureza:98.49%Cor e Forma:SolidPeso molecular:693.79Bicyclomycin benzoate
CAS:<p>Bicyclomycin benzoate (BCM benzoate, FR2054) is a broad-spectrum antibiotic and selective Rho protein inhibitor active against Gram-negative bacteria.</p>Fórmula:C19H22N2O8Cor e Forma:SolidPeso molecular:406.39Deoxypseudouridine
CAS:<p>Deoxypseudouridine is a nucleotide analog.</p>Fórmula:C9H12N2O5Cor e Forma:SolidPeso molecular:228.2Troxacitabine
CAS:<p>Troxacitabine, a DNA polymerase inhibitor, is potentially used for the treatment of acute myeloid leukemia (AML). In comparison with gemcitabine, troxacitabine was equally active against MiaPaCa and was more efficacious against Panc-01.</p>Fórmula:C8H11N3O4Pureza:98%Cor e Forma:SolidPeso molecular:213.19GSK-3/CDK5/CDK2-IN-1
CAS:<p>GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].</p>Fórmula:C21H22N4O2Cor e Forma:SolidPeso molecular:362.4335'-DMT-3'-TBDMS-ibu-rG
CAS:<p>5'-DMT-3'-TBDMS-ibu-rG is a modified nucleoside employed in deoxyribonucleic acid (DNA) synthesis.</p>Fórmula:C41H51N5O8SiCor e Forma:SolidPeso molecular:769.96Formycin A
CAS:<p>Formycin A shows antitumor and antiviral activities. Formycin A , a purine nucleoside antibiotic, is a potent human immunodeficiency virus type 1 (HIV-1) inhibitor with an EC50 of 10 μM.</p>Fórmula:C10H13N5O4Pureza:98%Cor e Forma:SolidPeso molecular:267.24Ethynylcytidine
CAS:<p>Ethynylcytidine is a nucleoside antimetabolite.</p>Fórmula:C11H13N3O5Pureza:98%Cor e Forma:SolidPeso molecular:267.245'-O-DMT-N6-ibu-dA
CAS:<p>5'-O-DMT-N6-ibu-dA can be utilized in the synthesis of oligodeoxyribonucleotides.</p>Fórmula:C35H37N5O6Cor e Forma:SolidPeso molecular:623.712'-Deoxy-2'-fluoro-5-iodouridine
CAS:<p>2'-Deoxy-2'-fluoro-5-iodouridine is a nucleoside, specifically a fluoro-modified and halo-nucleoside.</p>Fórmula:C9H10FIN2O5Cor e Forma:SolidPeso molecular:372.09PLK1-IN-6
<p>PLK1-IN-6: potent, selective PLK1 inhibitor, IC50 = 0.45 nM, hinders cancer cell growth.</p>Fórmula:C28H37N9O3Cor e Forma:SolidPeso molecular:547.65N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine
CAS:<p>N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine, catalog number T66118 and CAS number 64325-78-6, is a valuable organic compound for life sciences research.</p>Fórmula:C38H35N5O6Cor e Forma:SolidPeso molecular:657.727Tanuxiciclib
CAS:<p>Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.</p>Fórmula:C15H13FN6OCor e Forma:SolidPeso molecular:312.308NSC639828
CAS:<p>NSC639828 is an efficient inhibitor of DNA polymerase α, exhibiting a remarkable IC50 value of 70 μM. Additionally, NSC639828 demonstrates substantial antitumor activity, making it a promising candidate for cancer research.</p>Fórmula:C18H13BrClN5O3Cor e Forma:SolidPeso molecular:462.695'-O-TBDMS-dT
CAS:<p>5’-O-TBDMS-dT is a nucleoside with protective and modification effects.</p>Fórmula:C16H28N2O5SiCor e Forma:SolidPeso molecular:356.49MitoE10
CAS:<p>MitoE10 is an effective mitochondrial targeting antioxidant.</p>Fórmula:C42H55O5PSCor e Forma:SolidPeso molecular:702.926-Amino-5-nitropyridin-2-one
CAS:<p>6-Amino-5-nitropyridin-2-one, a pyridine derivative, serves as a nucleobase within hachimoji DNA, where it is specifically paired with 5-aza-7-deazaguanine.</p>Fórmula:C5H5N3O3Pureza:98%Cor e Forma:SolidPeso molecular:155.11Ribocil-C
CAS:<p>Ribocil-C is a selective inhibitor of the bacterial riboflavin riboswitch, a synthetic analogue of flavin mononucleotide (FMN), inhibits bacterial cell growth.</p>Fórmula:C21H21N7OSPureza:98%Cor e Forma:SolidPeso molecular:419.5Tibremciclib
CAS:<p>Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].</p>Fórmula:C28H32F2N8Pureza:98%Cor e Forma:SolidPeso molecular:518.6PHI-101
CAS:<p>PHI-101 is a checkpoint kinase 2 (Chk2) inhibitor that can be used for the study of refractory acute myeloid leukemia (AML) and ovarian cancer.</p>Fórmula:C19H19FN4O2SPureza:99.4%Cor e Forma:SolidPeso molecular:386.44YK-2168
CAS:<p>YK-2168 is a differentiated selective inhibitor of CDK9.</p>Fórmula:C16H18ClN5Cor e Forma:SolidPeso molecular:315.80Ref: TM-T200769
Produto descontinuado
